



## **Press Release**

### **Eurocor announces treatment of First Patients in International Randomized Freeride Study**

- **FREEWAY™ drug-eluting balloon used for treatment of de-novo or restenotic lesions in the SFA or Popliteal arteries**

**Bonn, Germany – January 25, 2012** – [Eurocor GmbH](#) announced today that the first patients in the Freeride study have been successfully treated with the drug-eluting balloon (DEB) [FREEWAY™](#). The study is lead-managed by Prof. Dr. Karl-Ludwig Schulte, Vascular Center Berlin/Ev. Königin Elisabeth Hospital in Berlin, Germany. The randomized, prospective, multicentre clinical study is being conducted at a total of 25 sites worldwide and involves 280 patients. The aim of the trial is to investigate the rate of clinically driven target lesion revascularization (TLR) using the Paclitaxel-eluting FREEWAY™ balloon in comparison to an uncoated balloon (POBA) in de-novo or restenotic lesions in the Superficial Femoral Artery (SFA) or Popliteal arteries (PI-segment).

Patients suffering from occluded, stenotic, reoccluded or restenotic lesions of 4 – 15 cm length will be treated either with a Paclitaxel-eluting balloon (Freeway™) or with POBA. A 6 and 12 month Duplex follow-up will be carried out as well as an angiographic follow-up in a subgroup at 6 months. This is an ongoing study and the first angiographic analysis and results are expected in spring 2013.

Prof. Dr. Schulte commented: “Stenotic or blocked lesions are serious problems, particularly in the SFA and PI-segment. Drug-eluting balloons offer a promising solution by reopening the vessel without leaving a stent; we are therefore looking forward to the results of this study. We hope this will result in fewer complications and less suffering for the patient.”

“We are pleased that the first patients have successfully been treated and are doing well. This is a key milestone for the company in its path to prove safety and efficacy of drug-eluting balloons also as a treatment for the SFA and PI-segment” said Dr. Rembert



Pogge von Strandmann, Director Clinical Department, Eurocor. "We trust that our DEB technology platform used on the FREEWAY™ balloon offers another significant therapeutic advantage for patients."

A study overview will be presented on the occasion of the [Leipzig Interventional Course \(LINC\) 2012](#) during the Eurocor Symposium on January 26<sup>th</sup>, 4:30 – 6:00 pm, Main Arena. For more details visit: [www.leipzig-interventional-course.de](http://www.leipzig-interventional-course.de) and [www.eurocor.de](http://www.eurocor.de).

-End-

### Media Contact

Eurocor GmbH

Claudia Tischendorf

Phone: +49 (0) 228 201 50 26

Email: [pressoffice@eurocor.de](mailto:pressoffice@eurocor.de)

### The Company:

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Bonn. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® – with innovative products such as DIOR® and FREEWAY™.

Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group.

For more information, please visit [eurocor.de](http://eurocor.de) and [optocircuits.com](http://optocircuits.com).